At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Closed 12-22 16:00:00 EST
2.49
+0.09
+3.75%
盘后2.54
+0.05+2.01%
19:57 EST
High2.54Low2.32Vol41.49K
Open2.37D1 Closing2.40Amplitude9.16%
Mkt Cap7.79MTradable Cap6.86MTotal Shares3.13M
T/O100.65KT/O Rate1.51%Tradable Shares2.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel
Reuters  ·  12-16
Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel
Silexion Therapeutics Initiated at Buy by Litchfield Hills
Dow Jones  ·  12-15
Silexion Therapeutics Initiated at Buy by Litchfield Hills
BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
Reuters  ·  12-02
BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026
THOMSON REUTERS  ·  12-02
Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026
Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026
THOMSON REUTERS  ·  12-02
Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
GlobeNewswire  ·  12-02
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers
Reuters  ·  12-02
Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers
BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026
Reuters  ·  11-26
BRIEF-Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026
Silexion Therapeutics completes toxicology studies for SIL204
TIPRANKS  ·  11-25
Silexion Therapeutics completes toxicology studies for SIL204
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
GlobeNewswire  ·  11-25
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Maxim Group Remains a Buy on Silexion Therapeutics (SLXN)
TIPRANKS  ·  11-14
Maxim Group Remains a Buy on Silexion Therapeutics (SLXN)
Silexion Therapeutics Corp : Maxim Group Cuts Target Price to $12 From $24
THOMSON REUTERS  ·  11-13
Silexion Therapeutics Corp : Maxim Group Cuts Target Price to $12 From $24
Silexion Therapeutics reports third quarter net loss of $7.5 million and cash balance of $9.2 million
Reuters  ·  11-12
Silexion Therapeutics reports third quarter net loss of $7.5 million and cash balance of $9.2 million
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
TIPRANKS  ·  10-25
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types
Reuters  ·  09-30
Silexion Therapeutics Announces Groundbreaking Preclinical Results for SIL204, Demonstrating Near-Complete Inhibition of Pan-KRAS Mutations Across Multiple Cancer Types
BUZZ-Silexion Therapeutics climbs on promising cancer drug data
Reuters  ·  09-30
BUZZ-Silexion Therapeutics climbs on promising cancer drug data
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-Kras Activity of Sil204, Demonstrating up to 99.7% Inhibition and First Evidence in Gastric Cancer
THOMSON REUTERS  ·  09-30
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-Kras Activity of Sil204, Demonstrating up to 99.7% Inhibition and First Evidence in Gastric Cancer
BRIEF-Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Reuters  ·  09-27
BRIEF-Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Silexion Therapeutics Files for $100 Million Mixed Shelf Offering
MT Newswires Live  ·  09-27
Silexion Therapeutics Files for $100 Million Mixed Shelf Offering
Silexion Therapeutics files $100M mixed securities shelf
TIPRANKS  ·  09-27
Silexion Therapeutics files $100M mixed securities shelf

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--